This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine. If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis for the CHMP recommendations, read the scientific discussion (also part of the EPAR).
Therapeutic Indication
### Therapeutic indication Treatment of the signs and symptoms of benign prostatic hyperplasia (BPH)
Therapeutic Area (MeSH)
ATC Code
G04CA04
ATC Item
silodosin
Pharmacotherapeutic Group
Urologicals
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| silodosin | N/A | 赛洛多辛 |
EMA Name
Silodyx
Medicine Name
Silodyx
Aliases
N/ANo risk management plan link.